Abingdon Health PLC (AIM:ABDX) and Senzo Health have announced a strategic partnership aimed at leveraging Senzo's innovative Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology.
Abingdon will provide contract development and manufacturing (CDMO) services to Senzo and its partners, enabling the development and manufacturing of new rapid tests using Senzo's advanced ALF platform.
Senzo is a frontrunner in the rapid diagnostics testing market, offering lab-quality accuracy within 10 minutes at a fraction of the cost.
While the technology is initially being applied to Covid antigen assays and other infectious disease tests, it has potential applications across clinical, animal health, food, plant pathogen, and environmental testing.
Abingdon, a leader in lateral flow tests, will provide services from initial concept to large-scale manufacturing. The UK-based company said it is capable of producing tens of millions of lateral flow tests per annum.
Chief executive Chris Yates commented: “We believe this strategic partnership agreement provides Senzo Health and its customers with access to Abingdon's best-in-class CDMO service to enable accelerated product development and time to market."